Low doses of eicosapentaenoic acid, docosahexaenoic acid, and hypolipidemic eicosapentaenoic acid derivatives have no effect on lipid peroxidation in plasma.
It was of interest to investigate the influence of both high doses of eicosapentaenoic acid (EPA) and low doses of 2- or 3-methylated EPA on the antioxidant status, as they all cause hypolipidemia, but the dose required is quite different. We fed low doses (250 mg/d/kg body wt) of different EPA derivatives or high doses (1500 mg/d/kg body wt) of EPA and DHA to rats for 5 and 7 d, respectively. The most potent hypolipidemic EPA derivative, 2,2-dimethyl-EPA, did not change the malondialdehyde content in liver or plasma. Plasma vitamin E decreased only after supplementation of those EPA derivatives that caused the greatest increase in the fatty acyl-CoA oxidase activity. Fatty acyl-CoA oxidase activity increased after administration of both EPA and DHA at high doses. High doses of EPA and DHA decreased plasma vitamin E content, whereas only DHA elevated lipid peroxidation. In liver, however, both EPA and DHA increased lipid peroxidation, but the hepatic level of vitamin E was unchanged. The glutathione-requiring enzymes and the glutathione level were unaffected, and no significant changes in the activities of xanthine oxidase and superoxide dismutase were observed in either low- or high-dose experiments. In conclusion, increased peroxisomal beta-oxidation in combination with high amounts of polyunsaturated fatty acids caused elevated lipid peroxidation. At low doses of polyunsaturated fatty acids, lipid peroxidation was unchanged, in spite of increased peroxisomal beta-oxidation, indicating that polyunsaturation is the most important factor for lipid peroxidation.
Vaagenes
H
H
Department of Clinical Biochemistry, University of Bergen, Haukeland Hospital, Norway.
Muna
Z A
ZA
Madsen
L
L
Berge
R K
RK
D042962:Acyl-CoA Oxidase; D000818:Animals; D000975:Antioxidants / Q000032:analysis; D001205:Ascorbic Acid / Q000032:analysis; D001769:Blood / Q000187:drug effects*; D004281:Docosahexaenoic Acids / Q000494:pharmacology*; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D015227:Lipid Peroxidation / Q000187:drug effects*; D008099:Liver / Q000737:chemistry; D008297:Male; D008315:Malondialdehyde / Q000032:analysis; D008830:Microbodies / Q000201:enzymology; D010088:Oxidoreductases / Q000032:analysis; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D013438:Sulfhydryl Compounds / Q000032:analysis / Q000097:blood; D013482:Superoxide Dismutase / Q000032:analysis / Q000235:genetics; D014801:Vitamin A / Q000032:analysis; D014810:Vitamin E / Q000032:analysis
D000975:Antioxidants; D000960:Hypolipidemic Agents; D012333:RNA, Messenger; D013438:Sulfhydryl Compounds; D014801:Vitamin A; D014810:Vitamin E; D004281:Docosahexaenoic Acids; D008315:Malondialdehyde; D015118:Eicosapentaenoic Acid; D010088:Oxidoreductases; D013482:Superoxide Dismutase; D042962:Acyl-CoA Oxidase; D001205:Ascorbic Acid